As Pharmaceutical and Clinical Trial Compliant Storage providers, BS3 provides clinical logistics solutions to pharmaceutical companies, delivering compliant expertise that optimise clinical supply chains, expand their reach, and consolidate the network through a single point of contact, and secure online portal.
In the dynamic landscape of medicinal cannabis, the importance of impeccable storage solutions cannot be overstated. At BS3, we recognize the critical role that proper storage plays in maintaining the quality of medicinal cannabis pharmaceuticals. Our state-of-the-art storage facilities are meticulously designed to meet and exceed industry standards, providing a secure environment that safeguards the potency and purity of every product.
Clinical trials are a vital component of the healthcare sector, playing a pivotal role in improving patient health outcomes, and significant resources are allocated to clinical logistics each year. The pharmaceutical industry like many others, grapples with many post-pandemic challenges that impose obstacles on supply chain teams, intensifying the need for enhanced efficiency, optimization, and visibility throughout clinical trials.
As a company dedicated to delivering the highest standards of service for specialised pharmaceutical storage & distribution solutions, we are proud to be able to announce that BS3’s strong growth continues. With our newest state-of-the-art Schedule 8/9 pharmaceutical storage vault commissioned mid 2023 already at 75% capacity, we are thrilled to unveil that a third vault is now currently under construction.
Ultra-low temperature (ULT) freezers are an absolute necessity for any organization handling temperature-sensitive specimens, therapies or mRNA vaccines. This essential cold storage equipment can effectively and safely preserve the cold chain for pharmaceutical, biotechnology, life sciences and healthcare industries. With the recent ultracold temperature requirements of mRNA-based COVID-19 vaccines, ULT cold storage has become a key focus for vaccine storage and distribution. Here are some best practices for understanding ULT freezer technology and its important connection to the logistics of last-mile delivery of temperature-sensitive medicines and vaccines.
In a competitive pharmaceutical storage market, differentiation is essential for success. At BS3 Pharmaceutical Storage & Distribution Specialists, we set ourselves apart by offering customized solutions, prioritizing long-term partnerships, upholding ethical business practices, and delivering unmatched value. Our focus is on meeting our clients' unique needs and exceeding their expectations rather than engaging in ruthless competition or catering to the highest bidder. By choosing BS3 Boutique Storage Specialists, clients can rest assured that they are partnering with a reliable and trustworthy provider that has their best interests at heart
Clinical trials are an important part of the drug development process, requiring careful planning and execution to ensure the safety and efficacy of the drugs being tested. Good Distribution Practices (GDP) is an essential part of this, guaranteeing quality standards and guidelines govern the storage, transportation, and distribution of pharmaceutical products.
We are thrilled to share that due to continued strong growth in demand, BS3 is embarking on the next phase of expansion and proudly announce the launch of our next state-of-the-art pharmaceutical Schedule 8/9 vault. This new vault not only expands our storage capabilities but also enhances the security and protection of your valuable assets. As a company dedicated to delivering the highest standards of service, we recognize the need for specialised storage solutions. Our Pharmaceutical Schedule 8/9 Vault has been designed with cutting-edge security features and advanced technology.
3rd February 2023, the Therapeutic Goods Administration (TGA) announced that from the 1st July 2023, medical use of MDMA and Psilocybin will be rescheduled from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) of the Poisons Standard. Which will enable authorised psychiatrists to prescribe these substances for treatment-resistant depression and treatment resistant post-traumatic stress disorder.
With the pharmaceutical industry contributing as much as 4-5% of global carbon emissions, it's great to see some of the leaders in the industry doing their part. Seven of the biggest have teamed up to pledge to work together to reduce carbon emissions in supply chains, health-care delivery and clinical trials. A joint effort that will enable the industry to achieve far more toward reducing industry emissions than individual companies could alone.